angelicin has been researched along with Liver Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, M; Huang, Q; Li, J; Li, R; Pan, G; Wang, F | 1 |
1 other study(ies) available for angelicin and Liver Neoplasms
| Article | Year |
|---|---|
Angelicin inhibits liver cancer growth in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Furocoumarins; Humans; Liver Neoplasms; Male; Mice; Mitochondria; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Xenograft Model Antitumor Assays | 2017 |